PLGA-entrapped recombinant r63 chimeric protein induces mucosal immunity against adherence and toxicity of Vibrio cholerae

Injectable inactivated whole-cell cholera vaccines provide limited protection due to poor mucosal immunity, leading to a shift toward oral cholera vaccines (OCVs). Chimeric recombinant vaccines can deliver multiple antigens simultaneously, enhancing immune specificity and simplifying production. This study aimed to develop a PLGA-encapsulated OCV using a chimeric protein for enhanced mucosal delivery and immune response. A synthetic gene encoding r63 was cloned into pET28a and expressed in E. coli BL21(DE3). The ~ 63 kDa His-tagged chimeric protein (r63) was purified via Ni-NTA affinity chromatography and entrapped in PLGA nanoparticles using a double emulsion-solvent evaporation technique. Particle size, zeta potential, SEM morphology, protein release kinetics, and encapsulation efficiency were evaluated. BALB/c mice were orally immunized with r63-PLGA, and IgG/IgA responses were measured by ELISA. Functional assays, including GM1-ELISA, Y-1 cell rounding, cAMP inhibition and rabbit ileal loop were performed to assess cholera toxin neutralization. In vitro adherence inhibition of V. cholera was investigated. The r63 was successfully expressed in E. coli and confirmed by SDS-PAGE and Western blotting. PLGA- r63 nanoparticles showed high encapsulation efficiency (90.16 ± 3.4%), a size of 221 ± 10 nm, and a zeta potential of - 11.8 ± 2 mV. Release studies indicated sustained protein release fitting a zero-order kinetic model. Oral immunization elicited robust serum IgG and fecal IgA responses against all antigens. Immunized sera prevented CTB binding to GM1 receptor, neutralized the enterotoxicity of cholera toxin in the Y1 cell line, and inhibited cAMP production. The immunized serum also suppressed cholera toxin activity in the ileal loop test by up to 79% and inhibited 66% of the bacterial adhesion to Caco2 cells. The orally delivered PLGA-r63 candidate vaccine effectively induced systemic and mucosal immunity against adherence and toxicity Vibrio cholerae.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-06-25
DOI
https://doi.org/10.1038/s41598-026-52925-6
Primary Topic
Vibrio bacteria research studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PLGA-entrapped recombinant r63 chimeric protein induces mucosal immunity against adherence and toxicity of Vibrio cholerae

Emad Kordbacheh, Shahram Nazarian, Hossein Samiei-Abianeh, Mohammad Behrozie
Scientific Reports
Vibrio bacteria research studies
article

PLGA-entrapped recombinant r63 chimeric protein induces mucosal immunity against adherence and toxicity of Vibrio cholerae

Emad Kordbacheh, Shahram Nazarian, Hossein Samiei-Abianeh, Mohammad Behrozie
article en

Abstract

Injectable inactivated whole-cell cholera vaccines provide limited protection due to poor mucosal immunity, leading to a shift toward oral cholera vaccines (OCVs). Chimeric recombinant vaccines can deliver multiple antigens simultaneously, enhancing immune specificity and simplifying production. This study aimed to develop a PLGA-encapsulated OCV using a chimeric protein for enhanced mucosal delivery and immune response. A synthetic gene encoding r63 was cloned into pET28a and expressed in E. coli BL21(DE3). The ~ 63 kDa His-tagged chimeric protein (r63) was purified via Ni-NTA affinity chromatography and entrapped in PLGA nanoparticles using a double emulsion-solvent evaporation technique. Particle size, zeta potential, SEM morphology, protein release kinetics, and encapsulation efficiency were evaluated. BALB/c mice were orally immunized with r63-PLGA, and IgG/IgA responses were measured by ELISA. Functional assays, including GM1-ELISA, Y-1 cell rounding, cAMP inhibition and rabbit ileal loop were performed to assess cholera toxin neutralization. In vitro adherence inhibition of V. cholera was investigated. The r63 was successfully expressed in E. coli and confirmed by SDS-PAGE and Western blotting. PLGA- r63 nanoparticles showed high encapsulation efficiency (90.16 ± 3.4%), a size of 221 ± 10 nm, and a zeta potential of - 11.8 ± 2 mV. Release studies indicated sustained protein release fitting a zero-order kinetic model. Oral immunization elicited robust serum IgG and fecal IgA responses against all antigens. Immunized sera prevented CTB binding to GM1 receptor, neutralized the enterotoxicity of cholera toxin in the Y1 cell line, and inhibited cAMP production. The immunized serum also suppressed cholera toxin activity in the ileal loop test by up to 79% and inhibited 66% of the bacterial adhesion to Caco2 cells. The orally delivered PLGA-r63 candidate vaccine effectively induced systemic and mucosal immunity against adherence and toxicity Vibrio cholerae.

Scientific Reports
Imam Hossein University (IR), Mashhad University of Medical Sciences (IR)
No poverty
Openalex Percentile: Top 8%
Vibrio bacteria research studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.